Marcuzzi A, Loganes C, Celeghini C, Kleiner G. Repositioning of Tak-475 In Mevalonate Kinase Disease: Translating Theory Into Practice. Curr Med Chem 2018;25(24):2783-2796.

Tricarico PMaura, Girardelli M, Kleiner G, Knowles A, Valencic E, Crovella S, Marcuzzi A. Alendronate, a double-edged sword acting in the mevalonate pathway. Mol Med Rep 2015;12(3):4238-42.

Tricarico PMaura, Piscianz E, Monasta L, Kleiner G, Crovella S, Marcuzzi A. Microglia activation and interaction with neuronal cells in a biochemical model of mevalonate kinase deficiency. Apoptosis 2015;20(8):1048-55.

Kleiner G, Zanin V, Monasta L, Crovella S, Caruso L, Milani D, Marcuzzi A. Pediatric patients with inflammatory bowel disease exhibit increased serum levels of proinflammatory cytokines and chemokines, but decreased circulating levels of macrophage inhibitory protein-1?, interleukin-2 and interleukin-17. Exp Ther Med 2015;9(6):2047-2052.

Tricarico PMaura, Kleiner G, Valencic E, Campisciano G, Girardelli M, Crovella S, Knowles A, Marcuzzi A. Block of the mevalonate pathway triggers oxidative and inflammatory molecular mechanisms modulated by exogenous isoprenoid compounds. Int J Mol Sci 2014;15(4):6843-56.

Bianco AMonica, Girardelli M, Vozzi D, Crovella S, Kleiner G, Marcuzzi A. Mevalonate kinase deficiency and IBD: shared genetic background. Gut 2014;63(8):1367-8.

Tricarico PMaura, Marcuzzi A, Zanin V, Kleiner G, Bianco AMonica, Crovella S. Serum amyloid A and cholesterol: a pivotal role on inflammation. Amyloid 2012;19(3):163-4; author reply 165-6.